IGC Pharma Completes Enrollment in Phase 2 CALMA Trial
POTOMAC, Md., June 10, 2026 IGC Pharma, Inc. (NYSE American: IGC) announced that its Phase 2 CALMA clinical trial...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
POTOMAC, Md., June 10, 2026 IGC Pharma, Inc. (NYSE American: IGC) announced that its Phase 2 CALMA clinical trial...
POTOMAC, Maryland, April 28, 2026 IGC Pharma, Inc. has announced expanded caregiver engagement efforts as its Phase 2 CALMA...
POTOMAC, Md., Feb. 9, 2026 — IGC Pharma, Inc. announced the expansion of its ongoing Phase 2 CALMA clinical...
